Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer
Status:
Terminated
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This Phase 1/2 study is designed to assess the following: safety and tolerability of
BIW-8962, Dose Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD), Recommended Phase 2
Dose (RP2D) in Phase 1 in subjects with advanced/recurrent lung cancers or mesothelioma and
preliminary efficacy in Phase 2 in subjects with advanced/recurrent Small Cell Lung Cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Korea Co., Ltd. Kyowa Kirin Korea Co., Ltd.